| Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML CD DiNardo, EM Stein, S De Botton, GJ Roboz, JK Altman, AS Mims, ... New England Journal of Medicine 378 (25), 2386-2398, 2018 | 1696 | 2018 |
| Functional genomic landscape of acute myeloid leukaemia JW Tyner, CE Tognon, D Bottomly, B Wilmot, SE Kurtz, SL Savage, ... Nature 562 (7728), 526-531, 2018 | 1439 | 2018 |
| Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation D Nijhawan, M Fang, E Traer, Q Zhong, W Gao, F Du, X Wang Genes & development 17 (12), 1475-1486, 2003 | 780 | 2003 |
| Proteogenomic and metabolomic characterization of human glioblastoma LB Wang, A Karpova, MA Gritsenko, JE Kyle, S Cao, Y Li, D Rykunov, ... Cancer cell 39 (4), 509-528. e20, 2021 | 647 | 2021 |
| Proteogenomic characterization of endometrial carcinoma Y Dou, EA Kawaler, DC Zhou, MA Gritsenko, C Huang, L Blumenberg, ... Cell 180 (4), 729-748. e26, 2020 | 467 | 2020 |
| Integrative analysis of drug response and clinical outcome in acute myeloid leukemia D Bottomly, N Long, AR Schultz, SE Kurtz, CE Tognon, K Johnson, M Abel, ... Cancer cell 40 (8), 850-864. e9, 2022 | 376 | 2022 |
| Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma C Huang, L Chen, SR Savage, RV Eguez, Y Dou, Y Li, ... Cancer cell 39 (3), 361-379. e16, 2021 | 341 | 2021 |
| Identification of interleukin-1 by functional screening as a key mediator of cellular expansion and disease progression in acute myeloid leukemia A Carey, DK Edwards, CA Eide, L Newell, E Traer, BC Medeiros, ... Cell reports 18 (13), 3204-3218, 2017 | 296 | 2017 |
| Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial A Burd, RL Levine, AS Ruppert, AS Mims, U Borate, EM Stein, P Patel, ... Nature medicine 26 (12), 1852-1858, 2020 | 203 | 2020 |
| Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101) GC Issa, I Aldoss, MJ Thirman, J DiPersio, M Arellano, JS Blachly, ... Journal of clinical oncology 43 (1), 75-84, 2025 | 181 | 2025 |
| FGF2 from marrow microenvironment promotes resistance to FLT3 inhibitors in acute myeloid leukemia E Traer, J Martinez, N Javidi-Sharifi, A Agarwal, J Dunlap, I English, ... Cancer research 76 (22), 6471-6482, 2016 | 164 | 2016 |
| Cloning, expression, and chromosomal localization of human long-chain fatty acid-CoA ligase 4 (FACL4) Y Cao, E Traer, GA Zimmerman, TM McIntyre, SM Prescott Genomics 49 (2), 327-330, 1998 | 158 | 1998 |
| The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance SK Joshi, T Nechiporuk, D Bottomly, PD Piehowski, JA Reisz, ... Cancer cell 39 (7), 999-1014. e8, 2021 | 140 | 2021 |
| Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors E Traer, R MacKenzie, J Snead, A Agarwal, AM Eiring, T O'Hare, ... Leukemia 26 (5), 1140-1143, 2012 | 126 | 2012 |
| Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid-and lymphoid-derived hematologic malignancies SE Kurtz, CA Eide, A Kaempf, V Khanna, SL Savage, A Rofelty, I English, ... Proceedings of the National Academy of Sciences 114 (36), E7554-E7563, 2017 | 122 | 2017 |
| Crosstalk between KIT and FGFR3 promotes gastrointestinal stromal tumor cell growth and drug resistance N Javidi-Sharifi, E Traer, J Martinez, A Gupta, T Taguchi, J Dunlap, ... Cancer research 75 (5), 880-891, 2015 | 121 | 2015 |
| Efficacy and safety of sabatolimab (MBG453) in combination with hypomethylating agents (HMAs) in patients (Pts) with very high/high-risk myelodysplastic syndrome (vHR/HR-MDS … AM Brunner, J Esteve, K Porkka, S Knapper, E Traer, S Scholl, ... Blood 138, 244, 2021 | 113 | 2021 |
| The cloning and characterization of a novel human diacylglycerol kinase, DGKι L Ding, E Traer, TM McIntyre, GA Zimmerman, SM Prescott Journal of Biological Chemistry 273 (49), 32746-32752, 1998 | 105 | 1998 |
| Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia CA Lachowiez, N Long, J Saultz, A Gandhi, LF Newell, B Hayes-Lattin, ... Blood Advances 7 (9), 1899-1909, 2023 | 103 | 2023 |
| Phase Ib study of the anti-TIM-3 antibody MBG453 in combination with decitabine in patients with high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) U Borate, J Esteve, K Porkka, S Knapper, N Vey, S Scholl, ... Blood 134, 570, 2019 | 98 | 2019 |
